Position
Parallel Advisors, LLC in Supernus Pharmaceuticals, Inc.
Back to the book · All holders of SUPN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $41$49.70 → $51.67
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 96 | $4.77K | — | — | — | 0.0% |
| Q1 2026 | 21 | $1.08K | $51.67 | $41 | −$3.73K | 0.0% |